Xeltis

Xeltis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Company Details

Employees
72
Founded
-
Address
De Lismortel 31, Eindhoven,north Brabant 5612 Ar,netherlands
Phone
41442697979
Email
in****@****tis.com
Industry
Medical Device
Website
xeltis.com
Keywords
Designer jobs.
HQ
Eindhoven, North Brabant
Looking for a particular Xeltis employee's phone or email?

Xeltis Questions

News

Sarasota Memorial Participates in Research Study Testing aXess™ Dialysis Conduit - Florida Hospital News and Healthcare Report

Sarasota Memorial Participates in Research Study Testing aXess™ Dialysis Conduit Florida Hospital News and Healthcare Report

Xeltis prepares for commercial launch after strong aXess trial results - PharmaTimes

Xeltis prepares for commercial launch after strong aXess trial results PharmaTimes

Xeltis has positive vascular access device data - MassDevice

Xeltis has positive vascular access device data MassDevice

Xeltis reports preliminary data for Xabg coronary artery bypass conduit - Medical Device Network

Xeltis reports preliminary data for Xabg coronary artery bypass conduit Medical Device Network

Xeltis sees encouraging preliminary data for Xabg coronary artery bypass conduit - BioWorld MedTech

Xeltis sees encouraging preliminary data for Xabg coronary artery bypass conduit BioWorld MedTech

Xeltis wins FDA breakthrough status, enrols first patient in pivotal trial - Clinical Trials Arena

Xeltis wins FDA breakthrough status, enrols first patient in pivotal trial Clinical Trials Arena

Axelera AI and Xeltis secure EU scaleup funding - ioplus.nl

Axelera AI and Xeltis secure EU scaleup funding ioplus.nl

Xeltis Receives IDE Approval from FDA for Initiation of US Pivotal Trial for aXess, its Restorative Vascular Access Conduit - Diagnostic and Interventional Cardiology

Xeltis Receives IDE Approval from FDA for Initiation of US Pivotal Trial for aXess, its Restorative Vascular Access Conduit Diagnostic and Interventional Cardiology

Xeltis reports positive data for coronary bypass conduit - MassDevice

Xeltis reports positive data for coronary bypass conduit MassDevice

Q&A: Xeltis implants first restorative hemodialysis graft in humans - Healio

Q&A: Xeltis implants first restorative hemodialysis graft in humans Healio

Xeltis Starts First-Ever Pivotal Trial of Its Synthetic Restorative Pulmonary Valve - Medical Device and Diagnostic industry

Xeltis Starts First-Ever Pivotal Trial of Its Synthetic Restorative Pulmonary Valve Medical Device and Diagnostic industry

Xeltis presents six-month first-in-human data on aXess graft - Vascular News

Xeltis presents six-month first-in-human data on aXess graft Vascular News

Xeltis to advance heart valve programs - Eindhoven University of Technology

Xeltis to advance heart valve programs Eindhoven University of Technology

Xeltis Begins Pivotal Trial for Pulmonary Valve That Grows With the Patient - Diagnostic and Interventional Cardiology

Xeltis Begins Pivotal Trial for Pulmonary Valve That Grows With the Patient Diagnostic and Interventional Cardiology

Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access graft - Vascular News

Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access graft Vascular News

Xeltis lands €32 million investment to develop restorative cardiovascular devices - Eindhoven University of Technology

Xeltis lands €32 million investment to develop restorative cardiovascular devices Eindhoven University of Technology

Xeltis’ vascular Axess graft implant sees no infection after one year - BioWorld MedTech

Xeltis’ vascular Axess graft implant sees no infection after one year BioWorld MedTech

Xeltis wins FDA IDE approval for restorative vascular access conduit pivotal trial - MassDevice

Xeltis wins FDA IDE approval for restorative vascular access conduit pivotal trial MassDevice

Two-Year Xeltis Bioabsorbable Valve Data Shows Positive Functionality - Diagnostic and Interventional Cardiology

Two-Year Xeltis Bioabsorbable Valve Data Shows Positive Functionality Diagnostic and Interventional Cardiology

First Bioresorbable Heart Valves Implanted to Enable Cardiovascular Restoration - Diagnostic and Interventional Cardiology

First Bioresorbable Heart Valves Implanted to Enable Cardiovascular Restoration Diagnostic and Interventional Cardiology

Another major investment round for Xeltis: €32 million for the development of restorative cardiovascular devices - ioplus.nl

Another major investment round for Xeltis: €32 million for the development of restorative cardiovascular devices ioplus.nl

Xeltis lands $52M for restorative heart valve technology - Fierce Biotech

Xeltis lands $52M for restorative heart valve technology Fierce Biotech

Cell-Based, Cell-Free Patches for Cardio Repair - Genetic Engineering and Biotechnology News

Cell-Based, Cell-Free Patches for Cardio Repair Genetic Engineering and Biotechnology News

Xeltis Develops First Ever Bio-Absorbable Heart Valve - Med Device Online

Xeltis Develops First Ever Bio-Absorbable Heart Valve Med Device Online

Top Xeltis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant